May 30, 2007 -- Daxor Corp., a medical instrumentation and biotechnology company, announced the June 2007 publication of the Journal of Nuclear Medicine Technology article, "Blood Volume Analysis: A New Technique and New Clinical Interest Reinvigorate a Classic Study."

May 30, 2007 -- The Channel Group, LLC announced today that it has formed Lesanne Life Sciences, LLC, a medical diagnostic company that is developing a simple blood test to detect the occurrence of a stroke.

Lesanne's diagnostic test is able to detect low levels of a patented protein biomarker that is present only in the brain and related central nervous system tissue of healthy individuals.

May 29, 2007 — Stentys says the results of preclinical testing of its bifurcated stent were reported at last week's EuroPCR 2007 Cardiovascular Congress.

Stentys is the first company to develop the next-generation of dedicated drug-eluting stents for treatment of blocked coronary artery bifurcations so that hundreds of thousands of patients might avoid open-chest surgery.

May 29, 2007 — Frost & Sullivan is launching a new end user study on the state of adoption for atrial fibrillation therapies in the U.S. cardiovascular market. Through more than 150 detailed interviews with electrophysiologists, cardiologists and other cardiovascular professionals, the company aims to elucidate key drivers and obstacles to adoption and utilization of various atrial fibrillation treatments.

May 29, 2007 — The Centers for Medicare & Medicaid Services (CMS) announced on May 25 a decision to provide coverage for Doppler monitoring of cardiac output in certain settings, removing the past noncoverage of this diagnostic test in these settings and adopting an evidence-based approach to healthcare.

May 29, 2007 — Boston Scientific Corp. has received CE Mark for its TAXUS Liberte Long paclitaxel-eluting coronary stent system, allowing doctors to treat longer coronary artery lesions with a single stent. TAXUS Liberte Long is the longest available drug-eluting stent.

May 29, 2007 — The FDA has cleared the CORDIS ENTERPRISE Vascular Reconstruction Device and Delivery System under the Humanitarian Device Exemption — it is used with embolic coils for the treatment of intracranial aneurysms. It consists of a self-expanding stent and a delivery system. The stent serves as a scaffold for embolic coils to prevent herniation of the coils into the parent vessel.

May 29, 2007 — Orqis Medical Corp., a clinical-stage company developing devices for the treatment of congestive heart failure (CHF), has announced that the 150th patient has been enrolled in the MOMENTUM Pivotal Trial. With 200 patients needed for study completion, the trial is now 75 percent enrolled.

The MOMENTUM Pivotal Trial is studying the use of the company's percutaneous Cancion System in heart failure patients. The novel Cancion System is designed to treat patients hospitalized with decompensated heart failure who inadequately respond to medical therapy.

May 29, 2007 — Doctors at University of Pittsburgh Medical School, (UPMC) have begun a study using an investigational cardiac device, the VentrAssist, Left Ventricular Assist System (LVAD) to see whether it can be used safely and effectively in patients with end-stage heart failure.

May 29, 2007 — Medtronic Inc. has enrolled the first patient in the landmark PROTECT clinical study, the largest randomized trial focusing on the safety of drug-eluting stents (DES).

The 8,800-patient trial will compare the Medtronic Endeavor zotarolimus-eluting coronary stent system and the Johnson & Johnson Cypher sirolimus-eluting stent, using key safety endpoints and other clinically relevant outcomes. The first patient was implanted in Germany.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now